It is important to look at the overall body of research available on the matter. What you have linked has no placebo-arm to compare to. In addition, only cells

It is important to look at the overall body of research available on the matter. What you have linked has no placebo-arm to compare to. In addition, only cells from 6 patients were tested. Furthermore, this is for extremely resistant CML patients who do not respond to imatinib (first line treatment). However, the introduction of second generation TKI inhibitors is now the standard of care in imatinib resistant CML patients. I haven’t referenced any particular pubmed entries since there are 6 or 7 second gen TKI’s, however, this reference by the American cancer society gives a good summary of available options. [1] https://www.cancer.org/cancer/chronic-myeloid-leukemia/treating/targeted-therapies.html https://www.cancer.org/cancer/chronic-myeloid-leukemia/treat...